Consequently, in the context of targeting ACS as an approach to treating infections, the selective inhibition of microbial, parasitic or fungal ACS enzymes relative to host ACSS2 would be likely to reduce potential adverse effects of those drugs. This evidence concerns the gene ACSS2 and infection.